GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avenue Therapeutics Inc (NAS:ATXI) » Definitions » Interest Coverage

Avenue Therapeutics (Avenue Therapeutics) Interest Coverage : No Debt (1) (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Avenue Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Avenue Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-3.71 Mil. Avenue Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Avenue Therapeutics has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Avenue Therapeutics Inc has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Avenue Therapeutics's Interest Coverage or its related term are showing as below:

ATXI' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: No Debt


ATXI's Interest Coverage is ranked better than
99.41% of 341 companies
in the Biotechnology industry
Industry Median: 148.11 vs ATXI: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Avenue Therapeutics Interest Coverage Historical Data

The historical data trend for Avenue Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Avenue Therapeutics Interest Coverage Chart

Avenue Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only No Debt No Debt No Debt - -

Avenue Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - No Debt No Debt No Debt No Debt

Competitive Comparison of Avenue Therapeutics's Interest Coverage

For the Biotechnology subindustry, Avenue Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avenue Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Avenue Therapeutics's Interest Coverage falls into.



Avenue Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Avenue Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Avenue Therapeutics's Interest Expense was $-0.33 Mil. Its Operating Income was $-14.54 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Avenue Therapeutics did not have earnings to cover the interest expense.

Avenue Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Avenue Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-3.71 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Avenue Therapeutics had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Avenue Therapeutics  (NAS:ATXI) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Avenue Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Avenue Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Avenue Therapeutics (Avenue Therapeutics) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule for CNS diseases, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
Executives
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Fortress Biotech, Inc. 10 percent owner 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Invagen Pharmaceuticals, Inc. 10 percent owner SITE B, 7 OSER AVE., HAUPPAUGE NY 11788
Alexandra Maclean officer: Chief Executive Officer C/O AVENUE THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NC 10014
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
David Jin officer: Int. PEO, Int. PFO, and COO C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Joseph Walter Vazzano officer: Chief Financial Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Curtis Gale Oltmans director C/O ARRAY BIOPHARMA INC., 3200 WALNUT ST., BOULDER CO 80301
Jay D Kranzler director 4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO CA 92121
Lucy Lu director, officer: President, CEO THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elizabeth Garrett Ingram director 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Thomas Gregory Moore director C/O AKORN, INC., 1925 WEST FIELD COURT, SUITE 300, LAKE FOREST IL 60045
Nishant Saxena director CIPLA HOUSE, PENINSULA BUSINESS PARK, LOWER PAREL, MUMBAI K7 400013
Jaideep Ashok Gogtay director CIPLA LTD., MUMBA CENTRAL, BESIDE CITY CENTER, MUMBAI K7 400008

Avenue Therapeutics (Avenue Therapeutics) Headlines

From GuruFocus